Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2466- CUR,    Regulatory Effects of Curcumin on Platelets: An Update and Future Directions
- Review, Nor, NA
*AntiAg↑, *antiOx↑, *Inflam↓, *12LOX↑, COX1↓, COX2/PTGS2↓, MMP9↓, NF-kB↓,
2579- CUR,  ART/DHA,    Curcumin-Artemisinin Combination Therapy for Malaria
- in-vivo, NA, NA
OS↑, toxicity↓,
2654- CUR,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
ROS↑, Catalase↓, SOD1↓, GLO-I↓, NADPH↓, TumCCA↑, Apoptosis↑, Akt↓, ER Stress↑, JNK↑, STAT3↓, BioAv↑,
2688- CUR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Var, NA - Review, AD, NA
*ROS↓, *SOD↑, p16↑, JAK2↓, STAT3↓, CXCL12↓, IL6↓, MMP2↓, MMP9↓, TGF-β↓, α-SMA↓, LAMs↓, DNAdam↑, *memory↑, *cognitive↑, *Inflam↓, *antiOx↑, *NO↑, *MDA↓, *ROS↓, DNMT1↓, ROS↑, Casp3↑, Apoptosis↑, miR-21↓, LC3II↓, ChemoSen↑, NF-kB↓, CSCs↓, Nanog↓, OCT4↓, SOX2↓, eff↑, Sp1/3/4↓, miR-27a-3p↓, ZBTB10↑, SOX9?, ChemoSen↑, VEGF↓, XIAP↓, Bcl-2↓, cycD1/CCND1↓, BioAv↑, Hif1a↓, EMT↓, BioAv↓, PTEN↑, VEGF↓, Akt↑, EZH2↓, NOTCH1↓, TP53↑, NQO1↑, HO-1↑,
2819- CUR,  Chemo,    Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury
- Review, Var, NA
*hepatoP↑, *Inflam↓, *antiOx↑, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, *ROS↓, *ALAT↓, *AST↓, *MDA↓, *NRF2↑, *COX2/PTGS2↑, *NF-kB↓, *ICAM-1↓, *MCP1/CCL2↓, *HO-1↑, CXCc↓,
2820- CUR,    Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways
- in-vitro, HCC, HepG2
*hepatoP↑, *ROS↓, tumCV↓,
2821- CUR,    Antioxidant curcumin induces oxidative stress to kill tumor cells (Review)
- Review, Var, NA
*antiOx↑, *NRF2↑, *ROS↓, *Inflam↓, ROS↑, p‑ERK↑, ER Stress↑, mtDam↑, Apoptosis↑, Akt↓, mTOR↓, HO-1↑, Fenton↑, GSH↓, Iron↑, p‑JNK↑, Cyt‑c↑, ATF6↑, CHOP/DDIT3↑,
2822- CUR,    Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies
- Analysis, Nor, NA
GLO-I↓,
2823- CUR,    Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis
- Study, Nor, NA
GLO-I↓,
2811- CUR,    Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study
- Human, Pca, NA
*antiOx↑, radioP↑, RadioS∅, *TAC↑, *SOD↓,
2817- CUR,    Neuroprotection by curcumin: A review on brain delivery strategies
- Review, Nor, NA
*BioAv↝, neuroP↑,
2812- CUR,    Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells
- in-vitro, AML, K562
TOP1↑, TOP2↑, eff↓,
2810- CUR,    Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials
- Review, Nor, NA
*SOD↑, *lipid-P↓, *GSH↑, *Catalase↑, *ROS↓,
2809- CUR,    Comparative absorption of curcumin formulations
- in-vivo, Nor, NA
BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↓, Half-Life↝,
2808- CUR,    Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation
- in-vitro, Liver, HUH7
Ferritin↓, IronCh↑, TumAuto↑, Apoptosis↑, eff↝, Dose↝,
2818- CUR,    Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways
- Review, AD, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *cognitive↑, *cardioP↑, other↑, *COX2/PTGS2↓, *IL1β↓, *TNF-α↓, NF-kB↓, *PGE2↓, *iNOS↓, *NO↓, *IL2↓, *IL4↓, *IL6↓, *INF-γ↓, *GSK‐3β↓, *STAT↓, *GSH↑, *MDA↓, *lipid-P↓, *SOD↑, *GPx↑, *Catalase↑, *GSR↓, *LDH↓, *H2O2↓, *Casp3↓, *Casp9↓, *NRF2↑, *AIF↓, *ATP↑,
2813- CUR,    Oxidative Metabolites of Curcumin Poison Human Type II Topoisomerases
- Review, NA, NA
TOP2↑,
2814- CUR,    Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management
- Review, Var, NA
*BioAv↓, *Inflam↓, *antiOx↑, AntiCan↑, CK2↓, GSK‐3β↓, EGFR↓, TOP1↓, TOP2↓, NF-kB↓, COX2/PTGS2↓, CRP↓,
2815- CUR,    Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin
*CK2↑,
2816- CUR,    NEUROPROTECTIVE EFFECTS OF CURCUMIN
- Review, AD, NA - Review, Park, NA
*neuroP↑, *Inflam↓, *antiOx↑, *BioAv↓, *AP-1↓, *NF-kB↓, *HATs↓, *HDAC↑, Dose↑, *ROS↓, *cognitive↑, *Aβ↓,
2980- CUR,    Inhibition of NF B and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation
- in-vivo, PC, NA
TumCG↓, p50↓, p65↓, NF-kB↓, Sp1/3/4↓, MMP↓, ROS↑,
2979- CUR,  GB,    Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
- in-vitro, Lung, H157 - in-vitro, Lung, H1299
EGFR↓, Sp1/3/4↓, ERK↓, MEK↓, Akt↓, S6K↓,
2978- CUR,    N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells
- in-vitro, Lung, A549
ROS↑, hTERT/TERT↓, Sp1/3/4↓, eff↓,
2977- CUR,    Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrosis Bronchial Epithelial Cells
- in-vitro, CF, NA
*TLR2↓, *Sp1/3/4↓,
2976- CUR,    Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor‑κB‑dependent pathway
- in-vitro, Oral, HSC3 - in-vitro, HNSCC, CAL33
tumCV↓, Sp1/3/4↓, p65↓, HSF1↓, NF-kB↓,
2975- CUR,    Curcumin inhibits proliferation, migration and neointimal formation of vascular smooth muscle via activating miR-22
- in-vivo, Nor, NA
*miR-22↑, *Sp1/3/4↓,
2974- CUR,    Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT15 - in-vitro, CRC, COLO205 - in-vitro, CRC, SW-620 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,
6238- CUSP9,    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
- Trial, GBM, NA
toxicity↓, TrxR↓, ROS↓, TumCI↓, TumCMig↓, TumCA↓, MMP2↓, MMP9↓, COX2/PTGS2↓, ALDH↓, TumAuto↑, P-gp/ABCB1↓, eff↑,
6235- CUSP9,    Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma
- in-vitro, GBM, NA
tumCV↓, NF-kB↓, HH↓, 5HT↓,
6236- CUSP9,  EP,    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro
- in-vitro, GBM, U251
Apoptosis↑, MOMP↓, Casp2↑, Bcl-2↓, Mcl-1↓, eff↑, OCR↓, OXPHOS↓, TumCMig↓,
6237- CUSP9,    CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
- NA, GBM, NA
PI3K↓, Akt↓, ROS↑, NF-kB↓, TNF-α↓, TLR2↓, other↓, TrxR↓, STAT3↓, MMPs↓, COX1↓, COX2/PTGS2↓, CA↓, ALDH↓, P-gp/ABCB1↓, HH↓, 5LO↓, mTOR↓, CycD3↓, Proteasome↓, other↓, MMP2↓, MMP9↓, ALDH↓, Copper↓,
6234- CUSP9,    In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
- Human, GBM, NA
TumCP↓, Apoptosis↑, TumCMig↓, tumCV↓, TumCG↓, cl‑Casp3↑,
6233- CUSP9,    A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs CUSP9 by the International Initiative for Accelerated Improvement of Glioblastoma Care
- Review, GBM, NA
other↝, QoL↑,
6239- CUSP9,    The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy
- in-vitro, GBM, NA
eff↑, tumCV↓, CSCs↓, Akt↓, mTOR↓, STAT↓,
6240- CUSP9,    A Pilot Clinical Study of CUSP9v3: Nine Repurposed Drugs Combined With Temozolomide for the Treatment of Recurrent Glioblastoma
- Human, GBM, NA
toxicity↝,
6241- CUSP9,    RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4
- Trial, GBM, NA
eff↑,
1910- CUSP9,    A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
- Analysis, GBM, NA
Dose↝, QoL↑, Dose↝,
6249- Cyc,    Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
HH↓, OCR↓, TumCP↓, Apoptosis↑, ROS↑, MMP↑, mtDam↑,
6242- Cyc,    The teratogenic Veratrum alkaloid cyclopamine inhibits Sonic hedgehog signal transduction
- in-vivo, Nor, NA
*Shh↓,
6243- Cyc,    Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened
- Study, Var, NA
AntiTum↑, HH↓, Smo↓,
6244- Cyc,    Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours
- in-vivo, Var, NA
HH↓, TumCG↓,
6245- Cyc,    Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers
- vitro+vivo, PC, NA
HH↓, Snail↓, E-cadherin↑, EMT↓, TumCI↓, ChemoSen↑, TumMeta↓, ALDH↓, eff↑,
6246- Cyc,    Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
HH↓, TumCP↓, TumCCA↓, TumCI↓, NF-kB↓, MMP2↓, MMP9↓, ERα/ESR1↓, cycD1/CCND1↓,
6247- Cyc,    Sonic Hedgehog Pathway Contributes to Gastric Cancer Cell Growth and Proliferation
- vitro+vivo, GC, MKN45
Shh↓, TumCP↓, TumCCA↓, Apoptosis↓, TumCG↓, cycD1/CCND1↓,
6248- Cyc,    The Hedgehog Inhibitor Cyclopamine Reduces β-Catenin-Tcf Transcriptional Activity, Induces E-Cadherin Expression, and Reduces Invasion in Colorectal Cancer Cells
- in-vitro, CRC, NA
HH↓, Apoptosis↑, Slug↓, Snail↓, Twist↓, EMT↓, β-catenin/ZEB1↓, E-cadherin↑, TumCI↓,
6250- Cyc,    Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse
- in-vivo, Nor, NA
*HH↓, *other↑,
6251- Cyc,    I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs
- Review, Var, NA
HH↓,
6252- Cyc,    Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance
- Review, Var, NA
*BioAv↓, Smo↓, HH↓, eff↑,
16- Cyc,  RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, N-cadherin↓, E-cadherin↑, Snail↓, TumCI↓, TumMeta↓,
7443- CYN,    Cynaropicrin, a sesquiterpene lactone, triggers apoptotic cell death in triple negative breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
TumCP↓, Apoptosis↑, BAX↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓,

Showing Research Papers: 2901 to 2950 of 8269
Prev Page 59 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   Copper↓, 1,   Fenton↑, 1,   GSH↓, 1,   HO-1↑, 2,   Iron↑, 1,   NQO1↑, 1,   OXPHOS↓, 1,   ROS↓, 1,   ROS↑, 7,   SOD1↓, 1,   TrxR↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,   MMP↓, 1,   MMP↑, 1,   mtDam↑, 2,   OCR↓, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GLO-I↓, 3,   NADPH↓, 1,   PPARα↝, 1,   S6K↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   Akt↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 9,   BAX↑, 1,   Bcl-2↓, 3,   Casp2↑, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   CK2↓, 1,   Cyt‑c↑, 1,   hTERT/TERT↓, 1,   JNK↑, 1,   p‑JNK↑, 1,   Mcl-1↓, 1,   MOMP↓, 1,   Proteasome↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

SOX9?, 1,   Sp1/3/4↓, 6,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   miR-21↓, 1,   miR-27a-3p↓, 1,   other↓, 2,   other↑, 1,   other↝, 1,   tumCV↓, 5,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↑, 1,   ER Stress↑, 2,   HSF1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   p16↑, 1,   P53?, 1,   TP53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 3,   CycD3↓, 1,   TumCCA↓, 2,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 4,   CD24↓, 1,   CSCs↓, 2,   EMT↓, 5,   ERK↓, 1,   p‑ERK↑, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   HDAC4↓, 1,   HH↓, 11,   mTOR↓, 3,   Nanog↓, 1,   NOTCH1↓, 1,   NOTCH1↝, 1,   OCT4↓, 1,   PI3K↓, 1,   PTEN↑, 1,   Shh↓, 1,   Smo↓, 2,   SOX2↓, 1,   STAT↓, 1,   STAT3↓, 4,   TOP1↓, 1,   TOP1↑, 1,   TOP2↓, 1,   TOP2↑, 2,   TumCG↓, 5,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AP-1↝, 1,   CA↓, 1,   CXCL12↓, 1,   E-cadherin↑, 4,   FAK↓, 1,   LAMs↓, 1,   MMP2↓, 5,   MMP9↓, 6,   MMPs↓, 1,   N-cadherin↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 3,   TGF-β↓, 1,   TumCA↓, 1,   TumCI↓, 6,   TumCMig↓, 4,   TumCP↓, 6,   TumMeta↓, 3,   Twist↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 2,   Hif1a↓, 1,   Hif1a↝, 1,   VEGF↓, 2,   ZBTB10↑, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 2,   COX2/PTGS2↓, 4,   CRP↓, 1,   CXCc↓, 1,   IL6↓, 1,   JAK2↓, 1,   NF-kB↓, 10,   p50↓, 1,   p65↓, 2,   TLR2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 7,   ChemoSen↑, 3,   Dose↑, 1,   Dose↝, 3,   eff↓, 2,   eff↑, 7,   eff↝, 1,   Half-Life↝, 1,   RadioS∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   EGFR↓, 2,   ERα/ESR1↓, 1,   EZH2↓, 1,   Ferritin↓, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   neuroP↑, 1,   OS↑, 1,   QoL↑, 2,   radioP↑, 1,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 162

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 7,   Catalase↑, 3,   GPx↑, 2,   GSH↑, 3,   GSR↓, 1,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 3,   MDA↓, 3,   NRF2↑, 3,   ROS↓, 8,   SOD↓, 1,   SOD↑, 4,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↓, 1,   ATP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↑, 1,   ALAT↓, 1,   LDH↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Casp3↓, 1,   Casp9↓, 1,   CK2↑, 1,   iNOS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↓, 1,   other↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

GSK‐3β↓, 1,   HDAC↑, 1,   HH↓, 1,   Shh↓, 1,   STAT↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   AP-1↓, 1,   miR-22↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   NO↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   COX2/PTGS2↑, 1,   ICAM-1↓, 1,   IL1β↓, 1,   IL2↓, 1,   IL4↓, 1,   IL6↓, 1,   INF-γ↓, 1,   Inflam↓, 7,   MCP1/CCL2↓, 1,   NF-kB↓, 2,   PGE2↓, 1,   TLR2↓, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   cognitive↑, 3,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 2,  
Total Targets: 64

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page